ADA Scientific Sessions 2026 Abstract

ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5

By Francesco Giorgino, Sherwin Dʼsouza, Lisa Ludwig, Janet Ash Tobian

Trial in peopleInterventions

The paper

Francesco Giorgino, Sherwin Dʼsouza, Lisa Ludwig, Janet Ash Tobian

Bari

ADA Scientific Sessions 2026 Abstract, 7 Jun 2026

Presented at ADA Scientific Sessions 2026, oral 1253-OR

doi.org/10.2337/db26-1253-or

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial